Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0KL3U
|
|||
| Former ID |
DNCL001841
|
|||
| Drug Name |
AR9281
|
|||
| Synonyms |
1-(Adamantane-1-yl)-3-(1-acetylpiperidine-4-yl)urea; UNII-4HA03Q8EZ9; 4HA03Q8EZ9; CHEMBL436774; 1-[(1-Acetylpiperidin-4-yl)-3-adamantan-1-yl]urea; 913548-29-5; Ar9281; AR-9281; Apau (enzyme inhibitor); SCHEMBL654229; 1-(1-Acetyl-piperidin-4-yl)-3-adamantan-1-yl-urea; SCHEMBL18464997; MolPort-023-222-910; HUDQLWBKJOMXSZ-UHFFFAOYSA-N; BDBM100423; BDBM50191854; ZINC36330562; AKOS030231617; J3137087F; US8501783, 1153; 1-(adamant-1-yl)-3-(1-acetylpiperidin-4-yl) urea; N-(1-Acetylpiperidin-4-yl)-N'-(adamant-1-yl) urea; N-(1-acetylpiperidin-4-yl)-N'-(adamant-1-yl)urea
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Hypertension [ICD-11: BA00-BA04; ICD-9: 401] | Phase 2 | [1] | |
| Company |
Ar te Therapeutics
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C18H29N3O2
|
|||
| Canonical SMILES |
CC(=O)N1CCC(CC1)NC(=O)NC23CC4CC(C2)CC(C4)C3
|
|||
| InChI |
1S/C18H29N3O2/c1-12(22)21-4-2-16(3-5-21)19-17(23)20-18-9-13-6-14(10-18)8-15(7-13)11-18/h13-16H,2-11H2,1H3,(H2,19,20,23)
|
|||
| InChIKey |
HUDQLWBKJOMXSZ-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 913548-29-5
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Soluble epoxide hydrolase (EPHX2) | Target Info | Inhibitor | [2] |
| KEGG Pathway | Arachidonic acid metabolism | |||
| Metabolic pathways | ||||
| Peroxisome | ||||
| Pathwhiz Pathway | Arachidonic Acid Metabolism | |||
| WikiPathways | Metapathway biotransformation | |||
| Arachidonate Epoxygenase / Epoxide Hydrolase | ||||
| Arachidonic acid metabolism | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT00847899) Evaluation of Soluble Epoxide Hydrolase (s-EH) Inhibitor in Patients With Mild to Moderate Hypertension and Impaired Glucose Tolerance. U.S. National Institutes of Health. | |||
| REF 2 | Orally bioavailable potent soluble epoxide hydrolase inhibitors. J Med Chem. 2007 Aug 9;50(16):3825-40. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.